Singapore: Genetic Technologies, a diagnostics company listed with the ASX and NASDAQ, has filed patent infringement suits in respect of its non-coding DNA technologies in the US. Cases have been filed against Genesis Genetics Institute, Genetics & IVF Institute, Reprogenetics and Medical Diagnostic Laboratories.

Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The company has operations in Australia and the US.

The company is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Its US subsidiary, Phenogen Sciences, offers novel predictive testing and assessment tools to help physicians proactively manage women's health. Phenogen's lead product, BREVAGen, is a first-in-class, clinically validated risk assessment test for non-familial breast cancer.